PT1453520E - Composições de estrogénio e outras hormonas com ascorbato, lisina, prolina e outras substâncias - Google Patents

Composições de estrogénio e outras hormonas com ascorbato, lisina, prolina e outras substâncias Download PDF

Info

Publication number
PT1453520E
PT1453520E PT01984842T PT01984842T PT1453520E PT 1453520 E PT1453520 E PT 1453520E PT 01984842 T PT01984842 T PT 01984842T PT 01984842 T PT01984842 T PT 01984842T PT 1453520 E PT1453520 E PT 1453520E
Authority
PT
Portugal
Prior art keywords
salts
pharmaceutical composition
proline
lysine
hydroxyproline
Prior art date
Application number
PT01984842T
Other languages
English (en)
Inventor
Matthias Rath
Aleksandra Niedzwiecki
Shrirang Netke
Ivanov Vadim
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of PT1453520E publication Critical patent/PT1453520E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (7)

  1. REIVINDICAÇÕES 1. Composição farmacêutica que compreende estrogénio, estradiol, etinilestradiol, estriol, noretisterona ou linestrenol, e lisina, sais de lisina, hidroxilisina ou sais de hidroxilisina, e ácido ascórbico ou sais de ascorbato, e prolina, sais de prolina, hidroxiprolina ou sais de hidroxiprolina.
  2. 2. Composição farmacêutica da reivindicação 1, que compreende, além disso, selénio ou sais de selénio, cobre ou sais de cobre, ferro ou sais de ferro e outros minerais ou oligoelementos.
  3. 3. Composição farmacêutica da reivindicação 1 ou 2, que compreende, além disso, sulfato de condroitina, gi icosaminoglicanos, proteoglicanos ou glicoproteínas da matriz extracelular.
  4. 4. Utilização de estrogénio, estradiol, etinilestradiol, estriol, noretisterona ou linestrenol, e lisina, sais de lisina, hidroxilisina ou sais de hidroxilisina, e ácido ascórbico ou sais de ascorbato, e prolina, sais de prolina, hidroxiprolina ou sais de hidroxiprolina, para a preparação de uma composição farmacêutica para controlo da fertilidade, contracepção, para terapia hormonal de substituição para aliviar os sintomas relacionados com a menopausa, para prevenir a osteoporose durante a menopausa, para prevenir doenças cardiovasculares durante a menopausa, e para prevenir outras perturbações durante a menopausa. 1
  5. 5. Utilização da reivindicação 4, em que a referida composição farmacêutica compreende, além disso, selénio ou sais de selénio, cobre ou sais de cobre, ferro ou sais de ferro e outros minerais ou oligoelementos.
  6. 6. Utilização da reivindicação 4 ou 5, em que a referida composição farmacêutica compreende, além disso, sulfato de condroitina, glicosaminoglicanos, proteoglicanos ou glicoproteinas da matriz extracelular.
  7. 7. Utilização de qualquer uma das reivindicações 4 a 6, em que a referida composição farmacêutica é para ser administrada por via sublingual, intravenosa, subcutânea, intramuscular, transdérmica ou parentérica. Lisboa, 02 de Novembro de 2006 2
PT01984842T 2001-12-14 2001-12-14 Composições de estrogénio e outras hormonas com ascorbato, lisina, prolina e outras substâncias PT1453520E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/014726 WO2003051371A1 (en) 2001-12-14 2001-12-14 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances

Publications (1)

Publication Number Publication Date
PT1453520E true PT1453520E (pt) 2006-12-29

Family

ID=8164723

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01984842T PT1453520E (pt) 2001-12-14 2001-12-14 Composições de estrogénio e outras hormonas com ascorbato, lisina, prolina e outras substâncias

Country Status (22)

Country Link
EP (1) EP1453520B1 (pt)
JP (1) JP2005511768A (pt)
KR (1) KR20040063950A (pt)
CN (1) CN1582152A (pt)
AT (1) ATE338555T1 (pt)
AU (1) AU2002233257B2 (pt)
BR (1) BR0116856A (pt)
CA (1) CA2467964C (pt)
CZ (1) CZ2004809A3 (pt)
DE (1) DE60122943T2 (pt)
DK (1) DK1453520T3 (pt)
EE (1) EE200300310A (pt)
ES (1) ES2272555T3 (pt)
HR (1) HRP20040611B1 (pt)
HU (1) HUP0500896A3 (pt)
IL (1) IL162013A0 (pt)
MX (1) MXPA04005771A (pt)
NO (1) NO20033555L (pt)
NZ (1) NZ532976A (pt)
PT (1) PT1453520E (pt)
SI (1) SI21785A (pt)
WO (1) WO2003051371A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
US20100167997A1 (en) * 2005-02-01 2010-07-01 Atyr Pharma, Inc. Method for stimulation collagen synthesis and/or kgf expression
WO2008139314A1 (en) * 2007-05-11 2008-11-20 Horphag Research (Luxembourg) Holding Sa Compositions and methods for treating joint disorders
WO2010146078A2 (en) * 2009-06-16 2010-12-23 Bergen Teknologioverføring As Novel uses of hydroxyproline compositions
JP6018800B2 (ja) * 2012-05-25 2016-11-02 ライオン株式会社 経口投与組成物
EP2857028A4 (en) * 2012-05-25 2016-04-06 Lion Corp AGENT CONTAINING ASCORBIC ACID DERIVATIVE AND USE THEREOF
JP6125899B2 (ja) * 2012-05-25 2017-05-10 ライオン株式会社 骨粗鬆症予防および／または改善剤
CN113244227B (zh) * 2020-02-12 2022-09-02 浙江医药股份有限公司新昌制药厂 一种17β-雌二醇与维生素C的分子复合物及其制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888631A (en) * 1959-02-24 1962-01-31 Upjohn Co Improvements in or relating to oral therapeutic compositions comprising steroids
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
CA2078804C (en) * 1991-10-01 2003-02-25 Takehiko Suzuki Manufacture and use of novel glycosides of catechol estrogens
EP1068868A3 (en) * 1997-07-08 2001-01-31 Rath, Matthias, Dr. med. Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration
DE29916231U1 (de) * 1999-09-15 2000-02-17 Renner, Jobst, Dr., 81479 München Multivitamin- und -mineralpräparat

Also Published As

Publication number Publication date
IL162013A0 (en) 2005-11-20
DE60122943T2 (de) 2007-04-26
AU2002233257A1 (en) 2003-06-30
NO20033555D0 (no) 2003-08-11
HRP20040611A2 (en) 2005-04-30
EE200300310A (et) 2003-10-15
MXPA04005771A (es) 2004-09-10
HRP20040611B1 (en) 2008-03-31
NZ532976A (en) 2006-02-24
AU2002233257B2 (en) 2008-08-14
BR0116856A (pt) 2004-08-03
CN1582152A (zh) 2005-02-16
DE60122943D1 (de) 2006-10-19
EP1453520A1 (en) 2004-09-08
ES2272555T3 (es) 2007-05-01
CZ2004809A3 (cs) 2004-12-15
KR20040063950A (ko) 2004-07-14
SI21785A (sl) 2005-12-31
CA2467964C (en) 2008-06-03
ATE338555T1 (de) 2006-09-15
HUP0500896A3 (en) 2008-04-28
CA2467964A1 (en) 2003-06-26
NO20033555L (no) 2003-10-02
DK1453520T3 (da) 2007-01-15
WO2003051371A1 (en) 2003-06-26
HUP0500896A2 (en) 2007-02-28
JP2005511768A (ja) 2005-04-28
EP1453520B1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
PT1453520E (pt) Composições de estrogénio e outras hormonas com ascorbato, lisina, prolina e outras substâncias
DE69532927D1 (de) Cyclophasiges hormonverfahren das antiprogestin und progestin enthält
BR0109334A (pt) Terapia de reposição hormonal
PT836506E (pt) Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
BR0113649A (pt) Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
BR0107683A (pt) Drospirenona para terapia de reposição de hormÈnio
BR9914419A (pt) Terapia para melhoria da percepção
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
BR9712274A (pt) Composição hormonal consistindo de um composto de estrogênio e um composto progestacional
BR0310085A (pt) Terapia de substituição de hormÈnio
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
BR0308968A (pt) terapia de reposição hormonal
BR0309621A (pt) Uso de estrógenos conjugados em combinação com trimegestona na terapia de substituição de hormÈnios
BRPI0606724A2 (pt) preparação farmacêutica para contracepção
LV13225B (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
ZA200403776B (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances.
LT5239B (lt) Estrogeno ir kitų hormonų kompozicija su askorbatu, lizinu, prolinu ir kitomis medžiagomis
Miller-Bass et al. Current states and future prospects of transdermal estrogen replacement therapy: Fertil. Steril. 1990 53/6 (961–974)
Moorjani et al. 91308364 Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with in menopausal women
UA89180C2 (ru) Дроспиренон для гормональной заместительной терапии